NeuroPace, Inc. (NPCE)

NeuroPace reported strong operational results with revenue growth in Q4 2025 and for the full year, driven by RNS System sales. Gross margin also expanded. The DIXI Medical commercial partnership concluded at the end of 2025. For 2026, the company anticipates typical seasonality, with growth moderating in the first half and re-accelerating in the second half. Key catalysts include regulatory progress on "Seizure ID" and the pursuit of an indication expansion for idiopathic generalized epilepsy (IGE). Investor sentiment has shown some skepticism, with the stock's RSI indicating overbought territory. The company's stock has received a consensus rating of "Moderate Buy" from analysts.

NeuroPace, Inc. experiences typical demand seasonality for its products and services. The company anticipates that growth will moderate in the first half of the year and then re-accelerate in the second half, consistent with historical patterns.

NeuroPace, Inc. is a medical device company focused on improving the lives of individuals with epilepsy through brain-responsive neuromodulation systems. Their flagship product is the RNS® System, an FDA-approved neurostimulation system for drug-resistant focal epilepsy, which includes the RNS neurostimulator, leads, a Patient Remote Monitor, a physician tablet, a patient data management system, and the nSight Platform. NeuroPace sells its products primarily to hospital facilities.

NeuroPace, Inc. primarily operates and sells its products in the United States. The company's headquarters are located in Mountain View, California.

NeuroPace's brand reputation is mixed, with strong operational performance but investor skepticism. The company has a consensus "Moderate Buy" rating, with bulls highlighting the improvement in patient quality of life and favorable macro trends. Investor anxiety exists due to doubts about growth sustainability and translating expansion into premium valuation, compounded by a history of net losses and the need for additional capital.

NeuroPace, Inc. has a significant portion of its stock owned by institutional shareholders, accounting for 78.12% of the company. Major institutional owners include Polar Capital Holdings Plc, Soleus Capital Management, L.P., Morgan Stanley, Orbimed Advisors Llc, BlackRock, Inc., Driehaus Capital Management Llc, Vanguard Group Inc, First Light Asset Management, LLC, Kent Lake PR LLC, and Deutsche Bank Ag. Accelmed Partners II LP is also a significant institutional holder. Individual insider ownership is also substantial, representing 83.99% of the company. URI Geiger is the largest individual shareholder, owning 8.88 million shares, which represents 26.38% of the company. Greg Shaw Garfield is another major individual insider owner.